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Abstract
The reduction of hepatic microsomal transfer protein (MTP) activity results in fatty liver, worsening hepatic steatosis and fibrosis 
in chronic hepatitis C (CHC). The G allele of the MTP gene promoter, -493G/T, has been associated with lower transcriptional 
activity than the T allele. We investigated this association with metabolic and histological variables in patients with CHC. A total 
of 174 untreated patients with CHC were genotyped for MTP -493G/T by direct sequencing using PCR. All patients were nega-
tive for markers of Wilson’s disease, hemochromatosis and autoimmune diseases and had current and past daily alcohol intake 
lower than 100 g/week. The sample distribution was in Hardy-Weinberg equilibrium. Among subjects with genotype 1, 56.8% 
of the patients with fibrosis grade 3+4 presented at least one G allele versus 34.3% of the patients with fibrosis grade 1+2 (OR 
= 1.8; 95%CI = 1.3-2.3). Logistic regression analysis with steatosis as the dependent variable identified genotypes GG+GT as 
independent protective factors against steatosis (OR = 0.4, 95%CI = 0.2-0.8; P = 0.01). The results suggest that the presence 
of the G allele of MTP -493G/T associated with lower hepatic MTP expression protects against steatosis in our CHC patients.
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Hepatitis C virus (HCV) infects about 2-3% of the world 
population (1), leading to chronic hepatitis in up to 60-80% 
of infected individuals and is associated with liver steatosis, 
fibrosis and insulin resistance (2,3). 
Chronic hepatitis C (CHC) is characterized by inflamma-
tory lesions in the liver and is now recognized as a systemic 
disease involving lipid metabolism, oxidative stress and 
mitochondrial function (4,5). The liver damage observed 
during CHC consists mainly of inflammation, periportal 
necrosis and fibrosis. The onset and progression of fibrosis 
are the direct result of local inflammation that triggers stel-
late cell activation (6). 
Both host and viral factors are implicated in the devel-
opment of HCV-associated steatosis, but their contribution 
varies widely as a function of viral genotype. This is also 
supported by the observation that the degree of liver steato-
sis is directly related to the level of HCV replication as mea-
sured by serum HCV-RNA, at least in patients infected with 
HCV genotype 3, in the absence of confounding metabolic 
causes of steatosis [type 2 diabetes, obesity or increased 
body mass index (BMI)] (7,8). However, there is strong 
evidence suggesting that some HCV proteins, particularly 
the structural capsid protein, core, and the non-structural 
protein, NS5A, can induce hepatic steatosis (9,10). 
Hepatic steatosis is a common histological feature of 
CHC and may contribute to fibrogenesis in this disease. The 
prevalence of steatosis in patients with CHC ranges from 
40 to 86% as compared with rates of 20 to 30% reported in 
patients with other liver diseases (11,12). The profibrogenic 
potential of steatosis is supported by several studies in which 
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a link has been demonstrated between necroinflammatory 
activity and steatosis grade (13,14).
It has been shown in cell lines that HCV core protein, 
which induces steatosis, also promotes oxidative stress 
(15,16). The profibrogenic properties of oxidative stress 
are mediated by direct DNA and mitochondrial damage, 
induction of hepatocyte apoptosis, and amplification of the 
inflammatory response (17). Additionally, the HCV core 
protein and non-structural proteins are thought to induce 
steatosis by interfering with lipid synthesis (18,19). 
In transgenic mice, the HCV core protein inhibits 
microsomal triglyceride transfer protein (MTP) leading to 
accumulation of intrahepatic triglyceride (20). MTP is a 
heterodimeric lipid transfer protein present on the luminal 
side of the endoplasmic reticulum (ER) in the liver, intestine 
and heart (21,22). Genetic polymorphisms can modulate 
the concentration of MTP in the ER and have an impact on 
the secretory pattern of lipoproteins (23). A common single 
nucleotide polymorphism (SNP) in the MTP gene promoter, 
-493G/T, has been described as functional, with the G al-
lele promoting less transcriptional activity than the T allele 
(24,25). Considering the possible interaction between MTP 
expression and HCV proteins, we investigated if genetic 
variations in the MTP gene could modulate metabolic and 
histological variables in patients with CHC from Brazil and 
we evaluated the MTP -493G/T SNP. 
Patients and Methods
Patients 
One hundred and seventy-four untreated patients with 
CHC (91 males and 83 females) presenting increased 
aminotransferase concentrations for at least 6 months and 
testing positive for anti-HCV antibodies (third-generation 
enzyme immunoassay) and for HCV-RNA (RT-PCR, Roche 
Cobas Amplicor 2.0, Roche Diagnostics, Switzerland) 
were enrolled between February 2007 and October 2009 
at the Liver Institute of Pernambuco. The HCV genotype, 
determined by the line probe assay (LiPA) (Innolipa HCV 
II; Immunogenetics, Belgium), was 1 in 113 cases and 
non-1 in 61 cases. 
This transverse study was conducted according to the 
Helsinki declaration of 1975. The protocol was approved by 
the Internal Review Board of Universidade de São Paulo 
and Universidade de Pernambuco and all subjects gave 
written informed consent to participate. 
Other causes of liver disease were excluded by ultra-
sound studies of the hepatobiliary system, viral serology, 
measurements of autoantibody titers and of serum iron, 
ferritin and transferrin saturation, ceruloplasmin and cop-
per concentrations, and alpha1-antitrypsin. Patients who 
had a >100 g/week alcohol intake determined by a detailed 
personal history, questioning of family members, and in-
vestigation of previous medical records, were excluded. 
Patients receiving immunosuppressive drugs or drugs 
causing steatosis (corticosteroids, antiepileptic agents, 
tamoxifen, and amiodarone) were also excluded. 
MTP -493G/T SNP was analyzed in all patients, but 
plasma samples were collected from only 138 patients at the 
time of liver biopsy and used to determine total cholesterol, 
low-density lipoprotein cholesterol (LDL-C), high-density 
lipoprotein cholesterol (HDL-C), triglycerides (Tg), alanine 
aminotransferase (ALT), aspartate aminotransferase 
(AST), gamma-glutamyl transferase (γGT), alkaline phos-
phatase (AP), fasting glucose and insulin concentrations, 
and homeostasis model assessment-insulin resistance 
(HOMA-IR): fasting insulin (µU/mL) x fasting glycemia 
(mM/22.5). Insulin resistance was considered to be present 
when HOMA-IR ≥2.5, a value based on a previous study 
conducted on the Brazilian population (26). 
Laboratory assays
Blood samples were centrifuged for 60 min to separate 
plasma, serum and leukocytes and stored at -80°C. Fasting 
glucose, total cholesterol and fractions, Tg, ALT, AST, AP, 
γGT, and insulin concentrations were measured by standard 
methods using automated techniques (Cobas, Roche). LDL-
C was determined by the Friedewald equation (27). 
Genomic DNA was extracted from peripheral blood 
leukocytes by the salting-out method. The promoter re-
gion of the MTP gene was amplified by the polymerase 
chain reaction (PCR) using the following set of primers: 
forward 5′-CTCATACAGTTTCACACATAAGG-3′, reverse 
5′-CAAACTCTGCTAAACCTAACCAA-3′ (which yielded a 
200-bp PCR product). The -493G/T SNP of the MTP gene 
was determined by direct sequencing of the PCR products 
using ABI PRISM dGTP BigDy Terminator v3.0 Ready Reac-
tion Cycle Sequencing (Applied Biosystems, USA) on an ABI 
PRISM 3130 XL Genetic Analyzer (Applied Biosystems).
Histological analysis 
Liver tissue was fixed in 4% formaldehyde and pro-
cessed for hematoxylin-eosin and Masson trichrome 
staining for histological analysis. A single experienced liver 
histopathologist who was blind to the patients’ clinical data 
and HCV genotype carried out the histological assessments. 
Stages of fibrosis and grades of inflammation were scored 
according to METAVIR; F0 (no fibrosis), F1 (portal fibrosis 
without septa), F2 (portal fibrosis with few septa), F3 (numer-
ous septa without cirrhosis), F4 (cirrhosis). Steatosis was 
graded 0-3 based on the percent of hepatocytes harboring 
lipid droplets in the biopsy (0 = none; 1 = 1-33%; 2 = 34-66%, 
and 3 representing >66% steatotic hepatocytes). 
Statistical analysis 
Data analysis was performed with the SPSS 15.0 soft-
ware. Normal distribution of the groups was preliminarily 
evaluated by the Kolmogorov-Sminorv test. Differences 
between groups were assessed by analysis of variance 
(ANOVA) when variables were normally distributed. The 
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chi-square test or the Fisher exact test was used to com-
pare categorical variables. Logistic regression analysis 
was performed with steatosis and fibrosis as dependent 
variables. The Pearson test was used to analyze the model 
that was assumed for the MTP -493G/T polymorphism 
(only TT homozygosity confers a higher activity to the MTP 
promoter). Results were considered to be significant when 
the P value was <0.05.
Results 
Clinical and biochemical analysis
Of the 174 patients studied, 52.3% (91/174) were males 
and 47.7% (83/174) were females. The biochemical charac-
teristics according to genotype and histological classification 
were analyzed for 138 patients. The patients were stratified 
according to viral genotype [1 (N = 93) vs non-1 (N = 45); 
Table 1], and according to histological grades of fibrosis 
[1+2 (N = 101) vs 3+4 (N = 37); Table 2] and of steatosis 
[no steatosis (N = 45) vs steatosis (N = 93); Table 3].
The biochemical characteristics according to genotype 
classification demonstrated that the concentration of total 
cholesterol was the only variable significantly different be-
tween patients with genotype 1 and genotype non-1 (158.01 
vs 138.58 mg/dL, respectively; P = 0.01; Table 1). CHC 
patients with grade 3+4 fibrosis presented higher concen-
trations of AST (87.14 vs 63.96 U/L; P = 0.01), ALT (105.7 
vs 79.44 U/L; P = 0.01) and γGT (120.92 vs 72.51 U/L; P 
= 0.02) than patients with fibrosis 1+2 (Table 2). The group 
of patients with steatosis presented lower concentrations of 
total cholesterol (146.24 vs 162.91 mg/dL; P = 0.02), and of 
LDL-C (78.44 vs 94.18 mg/dL; P = 0.03; Table 3).
MTP gene polymorphism 
The distribution of the -493G/T SNP genotypes was 
consistent with Hardy-Weinberg equilibrium. The genotype 
Table 1. Clinical and biochemical characteristics of chronic hepa-
titis C patients according to genotype classification.
Genotype 1
(N = 93)
Genotype non-1
(N = 45)
Age 54.06 51.59
Fasting glucose 92.58 100.13
HOMA-IR 2.72 3.35
AST (U/L) 68.69 73.24
ALT (U/L) 84.02 91.56
γGT (U/L) 86.06 84.31
AP (U/L) 83.03 72.67
Total cholesterol (mg/dL) 158.01 138.58*
HDL-C (mg/dL) 49.05 46.73
LDL-C (mg/dL) 88.00 74.44
Triglycerides (mg/dL) 105.89 91.69*
Reference values: glycemia = <100 mg/dL; HOMA-IR = <2.5; 
AST: males = 10-34 U/L, females = 10-36 U/L; ALT: males = 10-
44 U/L, females = 10-36 U/L; γGT: males = 11-50 U/L, females 
= 7-32 U/L; AP: males = 45-122 U/L, females = 32-104 U/L; total 
cholesterol = <200 mg/dL; HDL-C = >40 mg/dL; LDL-C = <130 
mg/dL; triglycerides = <150 mg/dL. HOMA-IR = homeostasis 
model assessment for insulin resistance; AST = aspartate ami-
notransferase; ALT = alanine aminotransferase; γGT = gamma-
glutamyl transferase; AP = alkaline phosphatase; HDL-C = high-
density lipoprotein cholesterol; LDL-C = low-density lipoprotein 
cholesterol. *P < 0.05 compared to genotype 1 (chi-square test).
Table 2. Clinical and biochemical characteristics of chronic hepa-
titis C patients according to fibrosis stage.
 
Fibrosis 1+2 
(N = 101)
Fibrosis 3+4 
(N = 37)
Age 52.26 55.07
Fasting glucose 92.81 101.14
HOMA-IR 2.73 3.47
AST (U/L) 63.96 87.14*
ALT (U/L) 79.44 105.70*
γGT (U/L) 72.51 120.92*
AP (U/L) 73.20 97.27
Total cholesterol (mg/dL) 152.63 149.05
HDL-C (mg/dL) 47.55 50.32
LDL-C (mg/dL) 85.01 79.65
Triglycerides (mg/dL) 101.32 101.11
Frequency GG+GT (%) 39.7% (N = 116) 48.3% (N = 58)
See Table 1 for reference values and explanation of abbrevia-
tions. *P < 0.05 compared to fibrosis 1+2 (chi-square test).
Table 3. Clinical and biochemical characteristics of chronic hepa-
titis C patients according to steatosis grade.
No steatosis 
(N = 45)
Steatosis
(N = 93)
Age 52.04 53.97
Fasting glucose 93.24 95.91
HOMA-IR 2.84 2.97
AST (U/L) 65.38 72.49
ALT (U/L) 79.44 89.88
γGT (U/L) 81.16 87.59
AP (U/L) 80.71 79.14
Total cholesterol (mg/dL) 162.91 146.24*
HDL-C (mg/dL) 50.16 47.40
LDL-C (mg/dL) 94.18 78.44*
Triglycerides (mg/dL) 95.09 104.25
Frequency GG+GT (%) 50% (N = 70) 37.5% (N = 104) 
See Table 1 for reference values and explanation of abbrevia-
tions. *P < 0.05 compared to no steatosis (chi-square test).
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frequencies were analyzed for 174 patients grouped accord-
ing to histological grades of fibrosis and steatosis: genotypes 
GG+GT occurred in 39.7% of the patients with 1+2 fibrosis 
and in 48.3% of the patients with 3+4 fibrosis (P = 0.05; Table 
2) and in 50% of the patients with no steatosis vs 37.5% of 
the patients with steatosis (P = 0.12; Table 3). 
Among subjects infected with virus genotype 1, 56.8% 
of the patients with grade 3+4 fibrosis presented at least 
one G allele vs 34.3% of the patients with grade 1+2 fibro-
sis (OR = 1.8; 95%CI = 1.3-2.3). This association was not 
observed in patients infected with HCV non-1 genotypes 
(Table 4). Logistic regression analysis with 3+4 fibrosis as a 
dependent variable in the whole population (HCV genotypes 
1 + non-1), however, did not identify the MTP genotype as 
a risk factor for the presence of fibrosis (Table 5).
Logistic regression analysis with steatosis as the de-
pendent variable in the whole population (HCV genotypes 
1 + non-1) identified genotypes GG+GT as independent 
protective factors against steatosis (OR = 0.4; 95%CI = 
0.2-0.8; P = 0.01; Table 6). 
Discussion
In this study, we set out to establish the role of the genetic 
MTP -493G/T SNP in the pathogenesis of steatosis and 
fibrosis in Brazilian patients with CHC. Our data showed that 
the G allele was more frequently present in CHC patients 
infected with genotype 1 with higher degrees of fibrosis. 
Also, genotypes GG+GT were found to be independent 
protective factors against steatosis in the whole population 
of CHC patients (genotype 1 + non-1).
The association of MTP -493G/T SNP with steatosis 
seems to differ between nonalcoholic fatty liver disease 
(NAFLD) and hepatitis C. While the T allele, associated 
with a higher MTP transcriptional activity, protects against 
the development of NAFLD by increasing Tg exportation 
from hepatocytes (28,29), it has been associated with ste-
atosis in CHC patients infected with genotype 3 probably 
by promoting the production of a more lipid-rich very low-
density lipoprotein (VLDL) that facilitates maturation of HCV 
precursors by optimizing HCV replication, thus contributing 
to a higher degree of steatosis (30).
However, data regarding the association of MTP -493G/T 
SNP with histological variables in CHC patients are still 
conflicting. Initially, Richardson et al. (31) examined this poly-
morphism among a set of SNPs in eight genes previously 
associated with hepatic fibrosis in a group of 326 patients 
with CHC and identified homozygosity for either the G or 
the T allele of the -493G/T SNP as independent risk factors 
for more rapid progression of liver fibrosis. This finding is 
intriguing in view of evidence from functional studies that 
G and T alleles are associated with different transcriptional 
activities of the MTP gene. 
Petit et al. (32), in a small series of 86 HCV-positive 
patients, 39 of them demonstrating signs of steatosis, did 
not find an association between the MTP -493G/T SNP 
and liver steatosis, while Zampino et al. (30) analyzed 102 
patients infected with HCV genotype 3 and showed higher 
degrees of steatosis, higher serum levels of HCV-RNA and 
more advanced fibrosis in carriers of the MTP T allele. Also, 
Mirandola et al. (33) evaluated a cohort of 298 CHC patients 
and found age, BMI, HCV genotype 3 and MTP T allele as 
independent risk factors for high grades of steatosis. Thus, 
the finding of the present study that genotypes GG+GT were 
Table 4. Allele frequencies of the MTP -493G/T polymorphism in 
chronic hepatitis C patients according to steatosis and fibrosis grades 
and according to viral genotypes.
MTP Genotype 1 Genotype non-1
TT GT+GG TT GT+GG
Fibrosis 1+2 50 (65.7%) 26 (34.3%)* 20 (50.0%) 20 (50.0%)
Fibrosis 3+4 16 (43.2%) 21 (56.8%) 14 (66.6%) 7 (33.4%)
No steatosis 29 (61.7%) 18 (38.3%) 15 (65.2%) 8 (34.8%)
Steatosis 37 (56.0%) 29 (44.0%) 19 (50.0%) 19 (50.0%)
*P < 0.05 compared to TT (Fisher exact test).
Table 5. Logistic regression analysis with fibrosis 3+4 as the de-
pendent variable.
Variables OR 95%CI
Gender: F/M 0.9 0.5-1.7
HOMA ≥2.5 0.8 0.4-1.8
LDL-C ≥130 2.1 0.4-10.0
HDL-C ≤40 1.0 0.4-2.3
Total cholesterol ≥200 1.7 0.3-8.3
Triglycerides ≥150 1.4 0.4-5.3
GG+GT (MTP) 1.4 0.7-2.6
See Table 1 for reference values and explanation of abbreviations. 
There were no statistically significant effects (Fisher exact test).
Table 6. Logistic regression analysis with steatosis as the de-
pendent variable.
Variables OR 95%CI
Gender: F/M 1.1 0.6-2.0
HOMA-IR ≥2.5 1.5 0.7-3.2
LDL-C ≥130 0.5 0.2-1.6
HDL-C ≤40 1.1 0.5-2.4
Total cholesterol ≥200 0.8 0.2-2.9
Triglycerides ≥150 0.6 0.2-1.8
GG+GT (MTP) 0.4 0.2-0.8*
See Table 1 for reference values and explanation of abbreviations. 
*P < 0.05 for GG+GT (MTP) as a variable (Fisher exact test).
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independent protective factors against steatosis points in 
the same direction as the results published by the latter two 
authors, with the difference that, in the present series, the 
association between the SNP and steatosis was observed 
regardless of HCV genotype. 
We observed lower concentrations of total serum cho-
lesterol and LDL-C in CHC patients with steatosis. Similar 
results have been reported by Corey et al. (34), who dem-
onstrated that serum lipids play a role in hepatitis C virion 
circulation and hepatocyte entry. In a cohort of 179 patients 
with CHC, these investigators compared the serum choles-
terol, LDL-C, HDL-C and Tg in 180 age-matched controls 
and showed that patients with HCV had lower concentrations 
of total cholesterol and LDL-C than the control group. No 
difference in serum concentration of HDL-C and Tg was 
found between the two groups. Probably the lipo-viral par-
ticles use the LDL-C receptors of hepatocytes as points of 
entry of the virus. Once inside the hepatocyte, replication 
depends of the lipid environment of the host (35-37). 
First, the severity of steatosis correlates with the level of 
HCV-RNA both in liver and in serum, especially in patients 
with genotype 3. Second, the fatty liver may significantly 
decrease if not disappear altogether when patients are suc-
cessfully treated with antiviral agents, especially patients 
with genotype 3. Steatosis may persist in most patients 
with non-3 genotypes, even in cases of sustained virologic 
response.
In a recent review, Negro (38) confirmed that hepatic 
steatosis is more frequent and severe in CHC patients with 
genotype non-1, suggesting the interaction of viruses with 
lipid metabolism. Also, in the present study we observed 
that total serum cholesterol was lower in CHC patients with 
genotype non-1 than in patients with genotype 1, although 
the concentration of Tg was also lower in this group, but 
with no significant difference between them (39,40). 
The results of the present study have important impli-
cations. The genetic MTP -493G/T polymorphism in CHC 
genotype 1 patients was more frequent among subjects with 
higher degrees of fibrosis although the GG+GT genotypes 
were found to be independent protective factors against 
steatosis in patients with CHC from Brazil. Moreover, the 
total serum cholesterol and LDL-C concentrations were 
lower in patients with steatosis.
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